- Home
- Publications
- Publication Search
- Publication Details
Title
Secukinumab: A Review in Ankylosing Spondylitis
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 4, Pages 433-443
Publisher
Springer Nature
Online
2019-02-22
DOI
10.1007/s40265-019-01075-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
- (2019) Stefan Schreiber et al. ANNALS OF THE RHEUMATIC DISEASES
- Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies
- (2018) I-Tsu Chyuan et al. MEDIATORS OF INFLAMMATION
- Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
- (2018) Paul Emery et al. PHARMACOECONOMICS
- 173 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase III clinical trial data
- (2018) Hasan Tahir et al. RHEUMATOLOGY
- Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
- (2018) Mitsumasa Kishimoto et al. Modern Rheumatology
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
- (2018) Jürgen Braun et al. RHEUMATOLOGY
- PMU28 - A CROSS INDICATION BUDGET IMPACT ANALYSIS OF SECUKINUMAB: A GREEK PERSPECTIVE
- (2018) M Kalogeropoulou et al. VALUE IN HEALTH
- PMS20 - BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
- (2018) C. Tozato et al. VALUE IN HEALTH
- PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT: A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE
- (2018) D. Kim et al. VALUE IN HEALTH
- PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
- (2018) P.A. Laires et al. VALUE IN HEALTH
- PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.
- (2018) S. Yahiaoui et al. VALUE IN HEALTH
- Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis
- (2018) Timo Purmonen et al. JOURNAL OF MEDICAL ECONOMICS
- Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies
- (2017) James C.-C. Wei et al. International Journal of Rheumatic Diseases
- The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases
- (2017) Taku Kuwabara et al. MEDIATORS OF INFLAMMATION
- Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
- (2017) H. Marzo-Ortega et al. ARTHRITIS CARE & RESEARCH
- Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
- (2016) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
- (2016) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab: A Review in Psoriatic Arthritis
- (2016) Matt Shirley et al. DRUGS
- Secukinumab: A Review in Ankylosing Spondylitis
- (2016) Hannah A. Blair et al. DRUGS
- Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
- (2016) Atul A. Deodhar et al. Arthritis & Rheumatology
- Secukinumab: A Review in Moderate to Severe Plaque Psoriasis
- (2015) Karly P. Garnock-Jones AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- THU0233 Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1)
- (2015) X. Baraliakos et al. ANNALS OF THE RHEUMATIC DISEASES
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started